1. Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.
- Author
-
Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, and Nixon DF
- Subjects
- Case-Control Studies, Cross-Sectional Studies, Humans, Lymphocyte Activation, Treatment Outcome, AIDS Vaccines immunology, CD8-Positive T-Lymphocytes immunology, Chemoprevention, HIV Envelope Protein gp120 immunology, HIV Infections immunology, HIV Infections prevention & control, HIV-1 immunology
- Abstract
Association of HIV-1-specific T-cell responses to infection risk in seronegative individuals is controversial. We quantified and phenotypically characterized gp120-specific T-cell responses in HIV-1 exposed, but uninfected subjects enrolled in the global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial. IFNγ ELISpot responses were detected in 24% of subjects irrespective of infection outcome. HIV-1 gp120 envelope-specific T-cell responses were more uniformly IFN-γ+TNF-α+Mip-1β+ in persistently seronegative subjects relative to subjects who later seroconverted (median frequency of 76.5% and 66.5%, respectively). IFNγ responses targeted the V2 loop for subjects who remained seronegative. HIV-1 gp120 envelope V2 loop-specific CD8 T-cell responses may help to protect against HIV-1 acquisition.
- Published
- 2016
- Full Text
- View/download PDF